Distinct mutational pattern of myelodysplastic syndromes with and without 5q– treated with lenalidomide
Myelodysplastic syndromes (MDS) are a heterogeneousgroup of clonal stem cell disorders characterised by ineffec-tive haematopoiesis leading to peripheral blood cytopeniasand an increased risk of transformation to acute myeloid leu-kaemia (AML) (Haferlachet al., 2014; Makishimaet al.,2017). One of th...
| Autores: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2020 |
| País: | España |
| Institución: | Universidad Católica de Valencia San Vicente Mártir |
| Repositorio: | RIUCV. Repositorio de la Universidad Católica de Valencia San Vicente Mártir |
| Idioma: | inglés |
| OAI Identifier: | oai:riucv.ucv.es:20.500.12466/3899 |
| Acceso en línea: | http://hdl.handle.net/20.500.12466/3899 |
| Access Level: | acceso abierto |
| Palabra clave: | Myelodysplastic syndromes del(5q) non‐del(5q) Mutations Lenalidomide 3205.04 Hematología |
| Sumario: | Myelodysplastic syndromes (MDS) are a heterogeneousgroup of clonal stem cell disorders characterised by ineffec-tive haematopoiesis leading to peripheral blood cytopeniasand an increased risk of transformation to acute myeloid leu-kaemia (AML) (Haferlachet al., 2014; Makishimaet al.,2017). One of the most common cytogenetic alterations isthe deletion of the long arm of chromosome 5q [del(5q)],which can be found isolated or with other alterations (10–30% of patients with MDS). Lenalidomide (LEN) has beenapproved for the treatment of patients with del(5q) low‐riskMDS and transfusion dependence. Almost 50% of patientswith del(5q) will show a complete cytogenetic remission and70% of them will reach transfusion independence (Listet al.,2006)... |
|---|